Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
14.89
+0.06 (0.40%)
At close: Oct 21, 2026, 4:00 PM EDT
14.70
-0.19 (-1.28%)
Pre-market: Oct 22, 2026, 8:30 AM EDT
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
958.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 18.94M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Rigel Pharmaceuticals | 276.79M |
| Monte Rosa Therapeutics | 28.73M |
| Aktis Oncology | 10.06M |
| SL Science Holding | 3.27M |
| Odyssey Therapeutics | 99.00K |
CGEM News
- 3 days ago - Cullinan: Zipalertinib demonstrates ‘clinically meaningful’ antitumor activity - TheFly
- 3 days ago - Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases - Business Wire
- 14 days ago - Cullinan Therapeutics doses first patient in CLN-049 trial - TheFly
- 14 days ago - Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 20 days ago - Cullinan Therapeutics initiates NDA for Zipalertinib - TheFly
- 20 days ago - New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - GlobeNewsWire
- 27 days ago - Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright - TheFly
- 27 days ago - Cullinan Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts